Inducible expression of a Th2-type CC chemokine thymus- and activation-regulated chemokine by human bronchial epithelial cells.
CCR4 is now known to be selectively expressed in Th2 cells. Since the bronchial epithelium is recognized as an important source of mediators fundamental to the manifestation of respiratory allergic inflammation, we studied the expression of two functional ligands for CCR4, i.e., macrophage-derived chemokine (MDC) and thymus- and activation-regulated chemokine (TARC), in bronchial epithelial cells. The bronchial epithelium of asthmatics and normal subjects expressed TARC protein, and the asthmatics showed more intense expression than the normal subjects. On the other hand, MDC expression was only weakly detected in the asthmatics, but the intensity was not significantly different from that of normal subjects. Combination of TNF-alpha and IL-4 induced expression of TARC protein and mRNA in bronchial epithelial A549 cells, which was slightly up-regulated by IFN-gamma. The enhancement by IFN-gamma was more pronounced in bronchial epithelial BEAS-2B cells, and a maximum production occurred with combination of TNF-alpha, IL-4, and IFN-gamma. On the other hand, MDC was essentially not expressed in any of the cultures. Furthermore, expressions of TARC protein and mRNA were almost completely inhibited by glucocorticoids. These results indicate that the airway epithelium represents an important source of TARC, which potentially plays a role via a paracrine mechanism in the development of allergic respiratory diseases. Furthermore, the beneficial effect of inhaled glucocorticoids on asthma may be at least in part due to their direct inhibitory effect on TARC generation by the bronchial epithelium.
Departments of Allergy and Rheumatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan.
T
T
Sekiya
M
M
Miyamasu
M
M
Imanishi
H
H
Yamada
T
T
Nakajima
M
M
Yamaguchi
T
T
Fujisawa
R
R
Pawankar
Y
Y
Sano
K
K
Ohta
A
A
Ishii
Y
Y
Morita
K
K
Yamamoto
K
K
Matsushima
O
O
Yoshie
K
K
Hirai
D000328:Adult; D001980:Bronchi / Q000737:chemistry / Q000187:drug effects / Q000276:immunology / Q000378:metabolism*; D002460:Cell Line; D002461:Cell Line, Transformed; D054414:Chemokine CCL17; D054422:Chemokine CCL22; D019742:Chemokines, CC / Q000037:antagonists & inhibitors / Q000096:biosynthesis* / Q000378:metabolism; D016207:Cytokines / Q000494:pharmacology; D004847:Epithelial Cells / Q000737:chemistry / Q000187:drug effects / Q000276:immunology / Q000378:metabolism*; D005260:Female; D005938:Glucocorticoids / Q000494:pharmacology; D006801:Humans; D007150:Immunohistochemistry; D007700:Kinetics; D008213:Lymphocyte Activation / Q000276:immunology*; D008264:Macrophages / Q000276:immunology; D008297:Male; D008875:Middle Aged; D018418:Th2 Cells / Q000276:immunology* / Q000378:metabolism*; D013950:Thymus Gland / Q000276:immunology*
C106230:CCL17 protein, human; C515482:CCL22 protein, human; D054414:Chemokine CCL17; D054422:Chemokine CCL22; D019742:Chemokines, CC; D016207:Cytokines; D005938:Glucocorticoids